OncoLink en espanõl
Share
Types of Cancer > Prostate Cancer > News
November 2009
In androgen-deprived prostate CA, zoledronic acid helps BMD even if started late
Short-course hormone therapy improves survival in medium-risk prostate CA
October 2009
In prostate CA, sexual function better with external beam radiotherapy vs cryoablation
Intralesional interferon shows promise for localized prostate cancer
Biochemical failure of high-intensity ultrasound for prostate CA redefined
Pros and cons seen with minimally invasive vs. open radical prostatectomy
September 2009
Treatment often avoided with watchful waiting for prostate cancer
Outcomes improving for conservatively managed prostate cancer
Functional outcome similar after open or laparoscopic prostatectomy
Retrovirus linked to prostate cancer
August 2009
Prostate cancer: racial gap narrows, men diagnosed earlier
Prostate cancer therapy may raise mortality in men with heart disease
Fasting serum insulin level tied to prostate cancer risk
Tallness may up risk of younger onset aggressive prostate cancer
Quality of life better with brachytherapy for endometrial cancer
Denosumab linked to reduced fracture risk during androgen deprivation therapy
July 2009
Robotic surgery for prostate cancer may improve functional outcome
Hormone therapy ups survival of radiation-treated men with prostate cancer
Baseline function predicts long-term QOL after prostate cancer therapy
June 2009
NSAIDs may affect PSA levels and prostate cancer risk
New form of radiotherapy for prostate cancer works in mice
Abirateron benefits patients with castration-resistant prostate cancer
Longer androgen suppression more effective in locally advanced prostate cancer
Risk score predicts several prostate cancer outcomes
Acrylamide exposure not associated with prostate cancer risk
May 2009
Prostate tumor hypoxia may confer resistance to radiotherapy
Young men with advanced prostate cancer have worse prognosis
Inactivated virus induces apoptosis in androgen-resistant prostate cancer cells
Molecular markers in prostate cancer tied to prognosis
Ferumoxtran-10 and MRI help detect metastasis of prostate cancer to lymph nodes
Agent Orange exposure increases risk of aggressive prostate cancer recurrence
April 2009
Statins cut risk of prostate cancer by a factor of three
Androgen deprivation therapy increases fracture risk and cardiovascular death
Hot flashes lessened with steroidal antiandrogen for prostate cancer
Bone health management suboptimal in prostate cancer patients
Longer hormone therapy may improve outcomes in advanced prostate cancer
New antiandrogen agents show promise against advanced prostate cancer
March 2009
Active surveillance safe for men with low-risk prostate cancer
No benefit seen with adjuvant radiotherapy after radical prostatectomy
Stereotactic radiotherapy "promising" for early prostate cancer
Bone-anchored sling relieves urinary incontinence after prostate surgery
PSA screening may yield small reduction in prostate cancer mortality
Selenium and vitamin E have tissue effects in prostate cancer patients
Up to two-thirds of prostate cancers "overdiagnosed"
Diabetes linked to reduced prostate cancer risk
Men in their late 70s with low PSA unlikely to develop aggressive prostate cancer
Prostate cancer anxiety tied to early use of androgen deprivation therapy
February 2009
Ionized serum calcium a potential biomarker of fatal prostate cancer
Surrogate endpoints may predict long-term survival in prostate cancer
Tumor cell count useful for monitoring advanced prostate cancer
Adjuvant radiotherapy useful for pT3N0M0 prostate cancer
Few major complications in 30 days after prostate radiotherapy
Biomarker, potential drug target identified for prostate cancer
Thalidomide may improve progression-free survival in prostate cancer
Engineered measles virus a novel oncolytic prostate cancer therapy
January 2009
Body mass index predicts biochemical recurrence after prostatectomy
Diet modification slows PSA doubling after prostate cancer treatment
Other health issues may be neglected in men with prostate cancer
Dietary fiber intake is not associated with prostate cancer risk
Novel androgen receptor variants tied to hormone-refractory prostate cancer
Her-2/neu expression and DNA index predict prostate cancer outcome
Skin cancer doesn't lower prostate, breast, and colorectal cancer risk
Noscapine may be effective for prostate cancer
With annual prostate cancer screening, new cases are less advanced
December 2008
Younger men with depression at risk for severe post-prostatectomy pain
Androgen deprivation for prostate cancer does not worsen cardiovascular mortality
BK virus may play role in prostate cancer
Chemotherapy does not delay appearance of castrate-resistant prostate cancer
Hormone therapy protects against hematuria after radiotherapy for prostate cancer
November 2008
Artificial sphincter restores urinary continence in prostate cancer patients
Antidiabetic drugs linked to lower prostate cancer risk
Agent Orange exposure linked to doubled risk of prostate cancer
Urine test may reduce unnecessary repeat prostate biopsies
October 2008
Urethral suspension technique improves post-prostatectomy continence
Urethral catheter-less robotic radical prostatectomy decreases patient discomfort
Alendronate enhances skeletal health during androgen-deprivation therapy
Low plasma cholesterol linked to less risk of high-grade prostate cancer
Hyperinsulinemia tied to higher mortality in overweight men with prostate cancer
Body weight, not diabetes, linked with prostate cancer death
Endoscopic prostatectomy effective in obese patients
September 2008
High fall risk seen in prostate cancer patients on androgen deprivation therapy
Pre-brachytherapy hormone therapy linked to greater mortality in older men
Radiation added to hormone therapy beneficial in locally advanced prostate cancer
Novel photodynamic therapy promising for recurrent prostate cancer
Height tied to risk of aggressive prostate cancer
Prostate irradiation raises long-term risk of colon cancer
Short-term mortality increased after prostate biopsy
Gene panel model predicts progression with high-risk prostate cancer
August 2008
Prostate cancer risk increased in obese men
Lower risk seen with radical prostatectomy versus watchful waiting
Recurrence rare after prostatectomy of organ-confined, lower grade cancer
Estrogen patches effective for androgen ablation in prostate cancer
Black-White differences again seen in prostate cancer prognosis
Physical development rate may be tied to prostate cancer risk
Prostate cancer screening not advised for men over 74
July 2008
Second-line doxorubicin/ketoconazole an option in hard-to-treat prostate cancer
Cognitive decline common with hormone therapy for prostate cancer
Active surveillance a good option for some men with early prostate cancer
Immunotherapy may boost prostate cancer response to hormone therapy
Limited benefit seen with docetaxel and rapid androgen cycling for prostate cancer
Anti-osteoclast monoclonal antibody prevents bone loss in prostate cancer
Lymphotropic virus may improve noninvasive detection of metastatic prostate cancer
Preop biomarkers predict prostate cancer relapse
Familial myeloma linked to increased incidence of prostate cancer, MGUS
Androgen blockade for prostate cancer leads to changes in body composition
Circulating tumor cell counts predict course of hard-to-treat prostate cancer
June 2008
Abnormal p53 boosts prostate cancer recurrence
Prostate screening of obese men calls for PSA adjustment
MRI combination best at predicting progression after prostate cancer treatment
HTI-286 shows antitumor activity in prostate cancer
Salvage radiotherapy prolongs prostate cancer survival for some
Lifestyle change alters gene expression in prostate cancer patients
Proscar lowers prostate cancer risk in all men
Prostate cancer therapy unrelated to metabolic syndrome
Vaginal brachytherapy effective for endometrial cancer
May 2008
Vitamin D may be linked to aggressive prostate cancer
Finasteride cuts prostate cancer risk without increase in aggressive disease
Brachytherapy stent benefits patients with advanced esophageal cancer
April 2008
Radical prostatectomy a good option for some older men with prostate cancer
Statin/NSAID combo inhibits androgen-independent prostate cancer growth
REFILE: Reductions in reimbursement linked to changes in prostate cancer treatment
Reductions in reimbursement linked to changes in prostate cancer treatment
March 2008
Investigational GnRH blocker shows potential for advanced prostate cancer
Pretreatment MRI identifies aggressive prostate cancer
Growth protein may provide new target for prostate cancer
Blood test indicates lymph node spread in localized prostate cancer
Potent brachytherapy effective against vaginal cancer
February 2008
Treatment breaks feasible for metastatic prostate cancer
Best treatment for localized prostate cancer remains unclear
Vaccine protects against prostate cancer in mice
Studies detect slew of new genes for prostate risk
Multiplex urine-based diagnostic test for prostate cancer promising
Androgens not associated with risk of ovarian cancer
Chemotherapy can restore endocrine sensitivity in prostate cancer
January 2008
Nerve-sparing prostatectomy improves subsequent continence
DNA fragments may predict prognosis of prostate cancer
Docetaxel every three weeks best for certain metastatic prostate cancers
Effective prostate cancer screening requires digital rectal exam
Comorbidity reduces benefits of androgen suppression in prostate cancer
Androgen-deprivation therapy linked to diabetes
Combination of gene variants strongly linked to prostate cancer
Alprostadil early after prostatectomy facilitates early return of erectile function
Blood transfusion does not increase prostate cancer recurrence risk
Nonfat milk linked to prostate cancer
December 2007
Polymorphism tied to aggressive prostate cancer
Nomogram points to prostate cancer surveillance candidates
Sorafenib active against hormone-refractory prostate cancer
Pelvic node irradiation does not improve survival in localized prostate cancer
Prostate-sparing cystectomy saves erectile function
Nuclear matrix proteins in prostate cancer higher in blacks than whites
November 2007
MR imaging-guided galvanotherapy promising for prostate cancer
Blockade site influences prostate biopsy pain
Obesity, overweight associated with increased prostate cancer mortality
Electromagnetic anisotropy detects prostate cancer noninvasively
Obesity may be protective in progressive prostate cancer
Salvage cryotherapy safe, effective after radiation failure for prostate cancer
October 2007
Brachytherapy effective for young men with prostate cancer
Statins may boost radiation efficacy in prostate cancer
Cardiac disease incidence rises early after starting androgen deprivation therapy
Nestin tied to prostate cancer metastasis
Prostate cancer linked to increased fracture risk
Gefitinib not active against hormone-refractory prostate cancer
Radiotherapy after prostatectomy of little benefit when surgical margins negative
Prostate biopsy site affects cancer detection
Prostate cancer no more aggressive in black men than white men
Topical glyceryl trinitrate eases prostate biopsy discomfort
Algorithm aids prostate cancer salvage therapy
September 2007
Cancer identified in one third of prostate biopsies
'Lumpectomy' may be possible in some cases of prostate cancer
Finasteride does not seem to cause high-grade prostate cancer
Asian men more likely to survive prostate cancer
T-cell coregulatory B7-H3 ligand is a marker of aggressive prostate cancer
August 2007
Prostate cancer screening interval doesn't affect interval tumor rate
External radiation and brachytherapy effective for high-risk prostate cancer
Statins seen to have little impact on androgen levels
Preservation of erectile function excellent after prostate brachytherapy
Obesity predicts prostate cancer recurrence after radiation therapy
Simple patient-education handouts may encourage prostate cancer screening
Zoledronic acid reduces bone damage in prostate cancer patients
Prostate cancer staging assisted by 3D transrectal ultrasonography
July 2007
Prostate cancer prediction not skewed by finasteride
Real-time elastography accurately detects prostate cancer
Venous thromboembolism associated with cyproterone use for prostate cancer
Chromosome 17 variants influence prostate cancer, type 2 diabetes risk
June 2007
Hormonal prostate cancer therapy may boost MI risk
Soy isoflavones may boost efficacy of radiotherapy for prostate cancer
BRCA2 mutation linked to aggressive prostate cancer
High calcium intake linked to increased prostate cancer risk
May 2007
Clodronate no apparent help in curbing prostate cancer
PSA drop not tied to negative repeat prostate biopsy
Hormone response can guide prostate cancer therapy
Patient-reported illness burden gives accurate prognosis in prostate cancer
Heavy multivitamin use may raise risk of advanced prostate cancer
Lower PSA cutoff would detect prostate cancer more often in men in their 40s
High BMI tied to treatment failure in prostate cancer
April 2007
Nerve-sparing laser approach to radical prostatectomy appears promising
Water diffusion tracks metastatic prostate cancer therapy response
MRI data useful in predicting insignificant prostate cancer
Ultraviolet radiation may protect against prostate cancer
Baseline PSA a poor predictor of lethal prostate cancer
Zoledronic acid for prostate cancer bone metastasis carries risk of renal toxicity
Metabolic syndrome associated with prostate cancer in African-American men
Loss of PTEN expression linked to prostate cancer metastasis
March 2007
Treatments for localized prostate cancer differ in side-effect profile
Annual zoledronic acid increases BMD in hypogonadal men with prostate cancer
Greater weight tied to prostate cancer mortality
PCA3 score best at predicting result of repeat prostate biopsy
Low-grade prostate cancer prediction model validated
Prostate mortality in blacks tied to healthcare access
Aggressive approach doubles high-grade prostate cancer survival
False-positive prostate cancer screen causes patient anxiety
Green tea plus painkiller slows prostate cancer
PSA test in mid-life predicts long-term risk of prostate cancer
PSA test in mid-life predicts prostate cancer in old age
February 2007
Pertuzumab extends survival for some prostate cancer patients
Low PSA does not rule out prostate cancer progression
Not all treatments for early prostate cancer equally effective: study
Satraplatin delays progression of advanced prostate cancer
Watchful waiting underutilized in men with low-risk prostate cancer
Nerve grafts may restore erectile function after prostatectomy
Age adjustment of PSA measures might improve prostate cancer screening
Prostatectomy approaches have similar continence impact
Obese men are more likely to be screened for prostate cancer
Selenium not linked to prostate cancer risk
January 2007
Low risk of prostate cancer seen in men with schizophrenia
Finasteride may distinguish between prostate cancer and benign disease
Survival rate highest with prostatectomy for localized prostate cancer
Improved nomogram helps gauge prostate cancer aggression
Early phosphodiesterase inhibitor use after brachytherapy aids erectile function
High-intensity focused ultrasound effective against high-risk prostate cancer
Prostate cancer treatment may shorten penis
Prostate cancer costs vary significantly by treatment type
Y chromosome may have role in prostate cancer
December 2006
Radical prostatectomy in older men not associated with greater excess mortality
Men with localized prostate cancer benefit from definitive treatment
Breast cancer family history raises prostate cancer risk in African Americans
Localized prostate cancer treatment lowers mortality in elderly men
Lower prostate cancer risk seen with metabolic syndrome
Decreased prostate cancer risk with NSAID use tied to genotype
November 2006
Diabetic men have a lower risk of prostate cancer
Myosin VI plays a key role in prostate cancer
Radiation after radical prostatectomy reduces recurrence rate, but not mortality
Dynamic contrast-enhanced magnetic resonance helps spot prostate cancer
Protein triggers new prostate cancer treatment
Metabolic syndrome a predictor of prostate cancer
PSA bounce after radiation for prostate cancer does not predict clinical failure
October 2006
Prostatectomy may help in highest-grade prostate cancer
GnRH agonist use for prostate cancer may up diabetes and heart disease risks
Tall, married men seen to have higher risk of prostate cancer
AZGP1 expression predicts metastasis after prostatectomy
Zoledronic acid ups bone mineral density in men receiving anti-androgen therapy
Alcohol intake does not affect prostate cancer risk
September 2006
Androgen deprivation therapy increases risk for diabetes, cardiovascular disease
Chronic inflammation tied to prostate cancer
Toremifene may help ward off prostate cancer
Biopsy of the prostate can be less painful
COX-2 expression in prostate cancer predicts recurrence
Increased risk of prostate cancer seen in rotating-shift workers
Angiogenin plays dual role in prostate cancer progression
Bicalutamide added to radiotherapy improves prostate cancer survival
PSA after treatment predicts survival in metastatic prostate cancer
Radical prostatectomy effective for some men with high-grade prostate cancer
August 2006
Chromosome 8 region linked to prostate cancer in African Americans
Targeted chimeric RNAs inhibit prostate cancer in murine model
Drug combo effective for prostate cancer cytoreduction before brachytherapy
Data support lower prostate specific antigen threshold for African American men
Hemoglobin drop a poor sign after androgen deprivation for prostate cancer
Family history of prostate cancer has little effect on prognosis
Altering dietary fatty acids slows prostate cancer growth in mice
July 2006
15% of men with prostate cancer undergo secondary chemotherapy
Bone scans not needed in men with low PSA after localized prostate cancer therapy
GI toxicity prolonged after prostate cancer irradiation
MUC1 vaccine may help slow prostate cancer after prostatectomy failure
Previous prostate radiation therapy linked to higher-grade bladder cancer
Prostate cancer vaccine improves disease-free survival
Radical prostatectomy for locally advanced prostate cancer feasible, effective
Hyperbaric oxygen may relief complication of prostate cancer therapy
Fear and misconception drive patients' choices for prostate cancer treatment
June 2006
Occult prostate cancer lymph node metastases tied to recurrence, mortality risk
UK'S NICE approves Sanofi's Taxotere for advanced prostate cancer
External radiation boosts brachytherapy control of prostate cancer
Obesity tied to disease recurrence after radiotherapy for prostate cancer
Urologist main determinant of hormone therapy use in prostate cancer
Folate intake may alter risk of advanced prostate cancer
Polymorphisms may influence survival in prostate cancer
May 2006
Modern cryotherapy an option for primary and recurrent prostate cancer
Nomogram predicts prostate cancer recurrence up to 10 years after surgery
Genitofemoral nerve grafts aid erectile function after prostatectomy
Androgen-deprivation monotherapy controls localized prostate cancer
Androgen deprivation therapy of prostate cancer lowers bone mineral density
First genetic marker of prostate cancer identified
Prostate cancer screening not supported for older men
April 2006
Surgery plus radiation does not control aggressive prostate cancer
GnRH therapy boosts diabetes risk in men with prostate cancer
Raloxifene acts against prostate cancer
Predictive model may improve assessment of prostate cancer risk
Histrelin subdermal implant effective against advanced prostate cancer
Testosterone levels rebound after androgen deprivation
Degarelix rapidly decreases testosterone in men with prostate cancer
March 2006
Confusion reigns in how men decide treatment for prostate cancer
Second-line therapy ineffective in hormone-refractory prostate cancer
'Androgen deprivation syndrome' tied to comorbidities, not therapy itself
Free PSA and hk2 enhance risk estimates of prostate cancer recurrence
Racial gap in prostate cancer survival due mostly to socioeconomic factors
February 2006
Alendronate prevents bone loss in men on androgen deprivation therapy
Age-adjusted PSA velocity may boost prostate cancer detection
Virus may cause prostate cancer, study hints
Prostate cancer harder to spot in obese men
Prostate re-screening interval could be safely extended for some
Depot delivery system maintains steady drug level in prostate cancer patients
Antioxidants of little benefit in preventing prostate cancer
Black men with highest prostate cancer risk have lowest screening rates
Genetic variants of IGF1 associated with prostate cancer risk
Algorithms for staging prostate cancer are improved with MRI
Long-term hormone therapy cost-effective for locally advanced prostate cancer
January 2006
Smoking linked to prostate cancer through hypermethylation of multiple genes
Statins improve outcome after brachytherapy for prostate cancer
Complexed PSA best for prostate cancer screening in black men: study
Palladium brachytherapy feasible as adjuvant treatment of early breast cancer
Prostate cancer screening may not reduce mortality
Hormone therapy for prostate cancer increases fracture risk
Biofeedback can reduce post-prostatectomy incontinence
Androgen deprivation affects memory in prostate cancer patients
December 2005
Cystoprostatectomy provides effective palliation for prostate cancer
Low serum testosterone levels associated with worse prostate cancer outcome
Prostate cancer not uncommon at PSA of less than 4 ng/mL
Serum Her-2/neu protein tied to prostate cancer progression
Androgen deprivation leads to bone loss in men with prostate cancer
Tyrosine kinase Ack1 plays role in prostate cancer development
Obesity increases risk of prostate cancer recurrence
DPPE added to chemo relieves pain in advanced prostate cancer
Satraplatin curbs hormone-refractory prostate cancer
November 2005
Long-term androgen deprivation beneficial for prostate cancer with high PSA
Digital rectal exam identifies prostate cancers with normal PSA
Herbal COX inhibitor acts against prostate cancer cells
Smaller prostate size associated with more aggressive cancers
Penile prosthesis aids life quality after prostatectomy
Prostate brachytherapy does not always lead to infertility
Antibody inhibits prostate tumor growth by Fc-independent mechanism
High-dose calcitriol potentiates docetaxel in advanced prostate cancer
Gene rearrangements often seen with prostate cancer
October 2005
High-dose strontium-90 brachytherapy effective for posterior uveal melanoma
Post-treatment PSA doubling time predicts prostate cancer-specific mortality
Single men with metastatic prostate cancer less likely to seek retreatment
Brachytherapy may change outlook for inoperable lung cancer
Biomarker for aggressive prostate cancer identified
FDA rejects Abbott prostate cancer drug Xinlay
Obesity increases prostate cancer recurrence risk
PSA doubling time points to prostate cancer outcome
Androgen deprivation beneficial in localized prostate cancer
September 2005
Post-prostatectomy fossa biopsy may be unnecessary
Gene mutation may raise prostate cancer risk in African Americans
Pomegranate extract promotes apoptosis of prostate cancer cells
Anti-tumor autoantibodies may improve accuracy of prostate cancer screening
Clusterin inhibitor promising against prostate cancer
Diet and exercise changes may slow prostate cancer
Statistical artifact may influence better prostate cancer outcomes
Some men with prostate dysplasia can be managed conservatively
MDM2 oncoprotein may predict prostate cancer metastasis
Calcitriol and NSAIDs together block prostate cancer cell growth
August 2005
PSA levels in young adulthood may predict prostate cancer risk
PSA screening lowers metastatic prostate cancer risk
Dietary pattern may increase prostate cancer risk
Brachytherapy adds to pediatric lymphoepithelioma therapy
LHRH peptide targets chemotherapy to ovarian cancer cells
Younger prostate cancer patients fare well with prostatectomy
Statin use linked to decreased risk of prostate cancer
Obesity associated with prostate cancer
Stat5 protein activation predicts early recurrence of prostate cancer
Testosterone treatment linked with prostate cancer
Postoperative radiotherapy useful for prostate cancer with capsular extension
Collagen method delivers siRNA to prostate cancer bone metastases
Antioxidant vitamin and mineral supplementation may help prevent prostate cancer
Racial variation in GSTP1 hypermethylation seen in prostate cancer
July 2005
Vaccine plus antiandrogen may be useful for prostate cancer with rising PSA
Risk factors for prostate cancer mortality after biochemical recurrence identified
Absorbable sling enhances early continence after radical prostatectomy
Prostate cancer hormone therapy may affect cognition
In prostate cancer treatment, quality of life better with radiation
PSA screening of asymptomatic men cuts risk of metastatic prostate cancer
Higher neuroserpin expression predicts worse outcomes in prostate cancer
No specific PSA value directly tied to prostate cancer risk
Extended NSAID use may cut prostate cancer risk
Prostate cancer radiotherapy does not raise bladder cancer risk
June 2005
Histone modification pattern predicts prostate cancer outcome
Cryosurgery effective palliation for endobronchial tumors
Expanded access to Xinlay for prostate cancer approved
Exercise improves sexual function after prostate cancer radiotherapy
Combination chemotherapy effective in hormone-refractory prostate cancer
Low expression of prostate cancer biomarker tied to progression, death
Gleason pattern combination helps grade prostate cancer
May 2005
Active surveillance obviates treatment for some men with prostate cancer
Androgen levels directly linked to breast cancer risk in young women
MMP-7 plays key role in prostate cancer-induced osteolysis
Overexpression of four genes distinguish prostate cancer from BPH
Testosterone stays low after stopping prostate cancer hormone therapy
New biomarker sensitive indicator of prostate cancer
Toremifene cuts prostate cancer risk in men with precancerous PIN
Radical prostatectomy in early prostate cancer improves 10-year outcomes
Circulating tumor cells predict metastatic prostate cancer survival
Salvage surgery good option after failed radiotherapy for prostate cancer
Stable course of localized prostate cancer supports conservative management
In utero exposure to estrogenic chemicals affects prostate growth in mice
April 2005
Stearoyl-CoA desaturase downregulated in prostate cancer
Longer screening intervals delay prostate cancer detection
Green tea may prevent prostate cancer in men at risk
MR spectroscopy aids in prostate cancer prognosis
Tamoxifen can reduce breast pain in prostate cancer patients
Testing during prostatectomy helps predict continence
Genetic protection from malaria may fuel prostate cancer in African-Americans
Prostate radiotherapy raises risk of rectal cancer
March 2005
Ethnicity, marital status affect treatment decisions in prostate cancer
Obesity may hasten prostate cancer diagnosis
Androgen deprivation for prostate cancer leads to metabolic disturbances
Long-term androgen deprivation for prostate cancer can be speedily reversed
Perineal radical prostatectomy useful for cancer in renal transplant recipients
US Medicare to cover prostate cancer drug
Brachytherapy for prostate cancer yields good long-term results
Men more likely to be screened for prostate cancer than colon cancer
MR method assesses prostate cancer aggressiveness noninvasively
High levels of vitamin E fractions linked to reduced risk of prostate cancer
Hormone therapy for prostate cancer affects cognition
February 2005
Finasteride use could cut prostate cancer deaths in US
Carotenoids may protect against prostate cancer
Modified docetaxel regimen more tolerable in hormone-refractory prostate cancer
High plasma folate levels may increase risk for prostate cancer
January 2005
Adjuvant therapy not indicated for low-risk prostate cancer patients
Low beta-catenin levels predict prostate cancer outcome
Obesity-related drop in PSA levels could mask prostate cancer
Plastic component boosts prostate cancer growth
MRI/CT planning may help prevent impotence after prostate radiotherapy
Diabetes associated with reduced risk of prostate cancer
Androgen-deprivation therapy for prostate cancer raises fracture risk
Dendreon prostate cancer drug fails to delay disease progression
Red wine may reduce prostate cancer risk
Dietary fats linked with prostate cancer aggressiveness
December 2004
"Biomarker roadmap" may help guide experimental prostate cancer therapy
"Watchful waiting" may be safe for carefully selected men with prostate cancer
PSA rise after radical prostatectomy helps predicts outcome
Adoptive immunotherapy effective in mice with metastatic prostate cancer
Low-fat diet feasible for prostate cancer patients
Transdermal estrogen: antiandrogen and osteoprotection for prostate cancer
New prostate cancer drug formulation wins FDA approval
Osteoporosis prevention neglected in men treated for prostate cancer
Ferromagnetic thermal ablation effective in locally recurrent prostate cancer
Green tea polyphenols inhibit IGF-1 signaling in prostate cancer model
November 2004
Radioactive iodine uptake seen after brachytherapy
Scale helpful in evaluating prostate cancer MRIs
New knowledge of androgen receptor modulation may alter prostate cancer therapy
Antisoma's telomere-targeting agent blocks experimental prostate cancer
Bicalutamide helpful in locally advanced prostate cancer
October 2004
Long-term prostatectomy outcomes better in African-American men
Blocking IGF1R gene makes prostate cancer cells vulnerable
Brachytherapy can preserve sexual function in men with localized prostate cancer
Osteoprotegerin best of proposed markers for prostate cancer bone metastases
Red wine consumption may lower prostate cancer risk
Docetaxel-containing regimens improve survival in advanced prostate cancer
Brachytherapy for prostate cancer sufficient without adjuvant treatment
September 2004
Lycopene plus vitamin E slows human prostate tumor growth in mice
IL-6 slows progress of prostate cancer tumors
Elderly blacks much less likely to be screened for prostate cancer
Androgen ablation response varies in metastatic prostate cancer
Rb gene deletion tied to prostate cancer onset
Urinary, bowel, sexual problems persist long after localized prostate cancer therapy
PSA no longer useful diagnostic marker of prostate cancer
August 2004
Obesity independently linked with poor outcome after prostate cancer surgery
MHC class I chain-related molecules may serve as biomarker for prostate cancer
Hepsin tied to progression of prostate cancer
Endorectal MRI useful for evaluating localized prostate cancer
Low-risk prostate cancer outcomes similar with observation or radiation therapy
Insulin-like growth factor I tied to prostate cancer risk
Brachytherapy inhibits in-stent neointimal hyperplasia in diabetics
Stat5 protein tied to prostate cancer virulence
July 2004
Antibody targets androgen-independent prostate cancer
Rate of PSA rise predicts death from prostate cancer after surgery
Phosphorylation inhibitors suppress prostate cancer bone metastases in mice
June 2004
Postoperative radiation therapy prolongs survival in prostate cancer patients
Onyvax says prostate cancer therapy shows promise
Balloon brachytherapy suitable alternative to standard breast cancer radiation
Adjuvant, salvage radiotherapy comparable after prostate cancer surgery
Docetaxel improves survival in hormone-refractory prostate cancer
Taxotere can increase survival in prostate cancer patients
May 2004
Gene marker may help spot prostate cancer metastases
Prostate cancer not rare among men with normal PSA levels
More evidence that diabetes may protect against prostate cancer
Endorectal coil MRI useful in detecting cancer recurrence after prostatectomy
Aberalix helpful in some advanced prostate cancer patients
Selenium levels inversely linked to risk of advanced prostate cancer
E-cadherin gene promoter polymorphism linked to hereditary prostate cancer
April 2004
Prostatectomy improves urinary tract symptoms in men with prostate cancer
Leading treatments for localized prostate cancer yield similar results
Soy metabolite shows novel anti-androgen effects in rats
Novel prostate cancer marker spots cancer when the biopsy is negative
Most low-PSA prostate cancers are clinically significant
Ejaculation does not raise prostate cancer risk
Urinary flow tied to prostate cancer brachytherapy outcome
March 2004
Prostate cancer therapy not tied to colorectal cancer risk
Early salvage radiotherapy treats "incurable" recurrent prostate cancer
Genetic profile points to prostate cancer outcome
Insulin-like growth factor tied to prostate cancer risk
Alternative antiandrogens effective after relapsed prostate cancer
February 2004
Low-fat diet boosts efficacy of androgen deprivation for prostate cancer in mice
New guidelines stress uniformity of clinical trials for relapsed prostate cancer
Aspirin use linked to lower prostate cancer risk
January 2004
Catheter-based brachytherapy after PCI is highly thrombogenic
Screening for prostate cancer leads to earlier detection
Androgen receptor blockade a potential therapy for ER-negative breast cancer
Age bias may influence treatment of localized prostate carcinoma
HHV-8 seropositivity linked with prostate cancer
Hormone therapy for prostate cancer may cause rapid bone loss
Antibody to p53 a marker for nonpalpable prostate cancer
10-year follow-up provides more accurate outcome of radiation for prostate cancer
Hepsin may represent new prognostic marker for prostate cancer
December 2003
Prostate zinc levels plus PSA levels aid in diagnosis of prostate cancer
Nuclear structure alterations predict outcome after radical prostatectomy for cancer
Earlier prostate cancer screening supported for black men
Increased androgen receptor expression leads to prostate cancer drug resistance
Androgen suppression for prostate cancer alters cognition somewhat
Older men may be over-screened for prostate cancer
November 2003
Decline in watchful waiting in prostate cancer
US approves new prostate cancer drug
Triple-drug regimen disappointing in hormone-refractory prostate cancer
Use of prostate brachytherapy has risen dramatically in US
Tomato powder, not lycopene, inhibits prostate cancer in rats
PCa-24 protein promising in prostate cancer detection
October 2003
UK says Casodex too risky in early prostate cancer
Complexed PSA no extra help in prostate cancer diagnosis
Lycopene helpful after orchidectomy for prostate cancer
Positive biopsy rate from prostate's affected side predicts cancer recurrence
Genetic polymorphism raises prostate cancer risk
Cialis may help erections after prostate surgery
Modern cryosurgery effective treatment for renal and prostatic tumors
Pintex study correlates Pin1 enzyme to severity of prostate cancer
Sildenafil does not promote prostate cancer growth in animal model
September 2003
Prostate cancer screening interval of 4 years misses few cancers
New method could help diagnose prostate cancer and other diseases
Outcome parameters, not procedure quantity, predict prostatectomy outcomes
New anti-prostate cancer compound gains FDA fast track status
Curative therapy benefits older men with localized prostate cancer
Prostate cancer risk highest when brother has the disease
Subcutaneous leuprolide delivers sustained effects in prostate cancer
August 2003
Vitamin D analog enhances radiation's ability to kill prostate cancer cells
Predictive nomogram for prostate cancer may reduce unnecessary biopsies
Some heavier men may have lower prostate cancer risk
High PSA levels no bar to prostate cancer surgery
Gene linked to hereditary prostate cancer may be involved in sporadic cases
African American prostate cancer patients receive fewer PSA tests
July 2003
Herbal COX-2 inhibitor induces prostate cancer cell apoptosis
Praecis says FDA extends review of prostate drug
Familial and sporadic prostate cancer cases share similar histories and outcomes
Telomerase inhibitor effective in prostate cancer cell lines
Smoking linked to increased risk of aggressive prostate cancer
Multiple genes may affect age at onset of hereditary prostate cancer
Androgen deprivation therapy may be overused for localized prostate cancer
Thapsigargin coupled to PSA substrate curbs experimental prostate cancer
Adding contrast improves ultrasound's ability to detect prostate cancer
Use of zinc supplements tied to possible increase in risk of prostate cancer
June 2003
Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
MRI with nanoparticles highly sensitive in detecting prostate cancer metastases
Annual prostate cancer screening tied to high overdetection rate
Prostate cancer survival improved with whole-pelvic radiation plus hormone therapy
Paraoxonase polymorphism confers increased risk of prostate cancer
Alpha-1 adrenergic blockade might be useful in treatment of prostate cancer
May 2003
Abnormal PSA test should be repeated before prostate biopsy
Biennial screening for prostate cancer sufficient when baseline PSA is low
Quality of care indicators developed for treatment of prostate cancer
Novel GnRH antagonist shows activity in men with prostate cancer
Biomarker combination linked to prostate cancer recurrence
Molecular markers point to radiotherapy outcome in prostate cancer
April 2003
Long-term evidence on prostate brachytherapy, cryoablation encouraging
Free PSA testing improves prostate cancer detection in men at high risk
Androgen suppression can be discontinued in some prostate cancer patients
Enzyme identified as potential therapeutic target in prostate cancer
Estrogen patches helpful in advanced prostate cancer
Quality of life not worsened by hormone-deprivation therapy after prostate brachytherapy
Prostate cancer more than twice as likely in obese men
March 2003
Leptin influences cellular differentiation and progression in prostate cancer
Increased risk of male breast cancer seen in prostate cancer patients
Prostate cancer now top male cancer in Britain
Patient age may not be relevant when selecting prostate cancer therapy
Imatinib plus paclitaxel reduces prostate cancer bone metastasis
Prostate cancer with nodal involvement may be curable with surgery
Predictors of PSA relapse after radiotherapy for prostate cancer identified
Smoking linked with increased risk of advanced prostate cancer
Green tea shows minimal efficacy against prostate cancer
February 2003
Endothelin-a receptor antagonist, atrasentan, fails in prostate cancer trial
Selenium supplementation may decrease DNA damage in prostate
January 2003
Adult body size not related to prostate cancer risk
Excess prostate cancer risk associated with high bone mass
Predictors of disease recurrence for high-risk prostate cancer identified
Older age predicts shorter survival with high-risk prostate cancer
Cytokeratin-positive cells predict distant metastases in prostate cancer patients
Sustained platelet activation observed after intracoronary brachytherapy
Prognosis of high Gleason score, low PSA prostate cancer surprisingly good
Salvage radiotherapy shows promise for PSA recurrence after prostatectomy
Radiofrequency appears superior to cryosurgery in preventing liver metastases
December 2002
Telomerase immunoreactivity of prostate tumors has diagnostic potential
FDA panel declines backing for Casodex to treat early prostate cancer
Hormone therapy before prostatectomy appropriate for stage T3 prostate cancer
Antigen-specific immunotherapy increases survival in mice with prostate tumors
Post-treatment PSA doubling time predicts prostate cancer-specific death
Brachytherapy for prostate cancer equally effective for blacks and whites
Net benefit of prostate cancer screening cannot be determined
Most therapies provide similar outcomes for early prostate cancer
November 2002
Aspirin and other NSAIDs do not appear to reduce prostate cancer risk
Excision plus brachytherapy may obviate mastectomy for recurrent breast cancer
Prophylactic use of alpha-blockers optimal after prostate brachytherapy
Failure of flutamide treatment in prostate cancer traced to EGF receptor signaling
Diet rich in flaxseed protects mice from prostate cancer
October 2002
BRCA2 mutation may increase prostate cancer risk
HER2 expression weak in primary prostate cancers
Low recurrence rate of breast cancer seen with brachytherapy
Vasectomy does not increase prostate cancer risk
Positive surgical margins significant predictor of recurrence in prostate cancer
Overexpressed protein tied to metastatic prostate cancer
FDA clears brachytherapy breast irradiation device
Algorithm helps predict lymph node metastases in prostate cancer
Zoledronic acid reduces risk of skeletal events with metastatic prostate cancer
September 2002
Infection with C. trachomatis may protect against prostate cancer
Brachytherapy causes iatrogenic shedding of prostate cancer cells
Catheter-based brachytherapy prevents stent restenosis in diabetic patients
Mutations in MSR1 gene linked to prostate cancer
Surgery and watchful waiting for early prostate cancer provide similar outcomes
Low-fat high-fiber diet does not lower PSA levels, prostate cancer risk
August 2002
Surgery, radiotherapy equivalent for localized prostate cancer
Local treatment may improve outcomes in advanced prostate cancer
Locally persistent prostate cancer can result in a late wave of metastases
Lymph node dissection essential for correct prostate cancer staging
New drug shows promise against hard-to-treat breast and prostate cancers
Bicalutamide reduces risk of prostate cancer progression
High calorie, fat, and calcium diet linked to higher prostate cancer risk
Younger prostate cancer patients at risk for treatment failure with radiotherapy
Estrogen receptor signaling modulates human prostate cancer telomerase activity
Nomogram accurately predicts likelihood of prostate cancer recurrence
July 2002
Androgen blockade may provide long-term control of localized prostate cancer
Complications of prostate cancer treatment more common than often reported
Radiotherapy for prostate cancer has little effect on urinary function
Adding androgen suppression to radiotherapy improves prostate cancer survival
Polyphenols in red wine induce apoptosis of prostate cancer cells
Avoidant coping increases stress of prostate cancer diagnosis
Cancer-associated antibody test could improve specificity of prostate screening
Prostate cancer overdiagnosis due to PSA screening "considerable"
June 2002
Selective screening based on family history misses most prostate cancers
Vasectomy not linked to prostate cancer
Ratio of cathepsin B to stefin A predicts node involvement in prostate cancer
High lycopene levels may protect against prostate cancer
Serial bone testing may detect fracture-prone prostate cancer patients
May 2002
Prostate cancers often missed on initial biopsy
Blacks more likely than whites to have prostate cancer recurrence
Oncoprotein shows promise as predictor of prostate cancer survival
April 2002
"Watchful waiting" approach to prostate cancer may benefit selected patients
Nerve-sparing prostatectomy recommended whenever possible
Vaccine elicits response in patients with advanced prostate cancer
High rate of lymph node metastasis found in clinically localized prostate cancer
Herbal supplement for prostate cancer contains indomethacin, DES and warfarin
Radiation implants for prostate cancer can move to lungs
PSA screening not associated with decreased prostate cancer mortality
Gene overexpressed in prostate cancer identified
March 2002
Daily NSAID use may reduce prostate cancer risk in older men
Initial androgen deprivation therapy for prostate cancer affects sexual function
Bone scan may be unnecessary for some men with prostate cancer
Tomato product intake may reduce prostate cancer risk
DES can prevent adverse bone effects of prostate cancer therapy
February 2002
Brachytherapy complements laser therapy in esophageal cancer palliation
Brachytherapy viable alternative to amputation for penile cancer
Prostate cancer trends in France began to improve in early 1990s
Vaginal brachytherapy as effective as whole pelvic radiation
January 2002
BioPince needle has pros and cons for prostate biopsy
FDA approves one-month formulation of leuprolide for prostate cancer
Prognostic factors identified for prostatectomy outcome in high grade cancer
Germline mutations in ribonuclease gene linked to prostate cancer
Enzyme prompts bone loss in prostate cancer
Vegetarian diet, stress management slows PSA rise in prostate cancer patients
December 2001
Bilateral orchiectomy declining in US men with prostate cancer
Xenogeneic antigen vaccine promotes vigorous response to prostate cancer
Increased needle biopsy sampling detects earlier stage prostate cancer
Possible tumor suppressor gene linked to prostate cancer
Tomato sauce consumption decreases DNA damage in prostate cancer patients
Supplemental selenium may reduce prostate cancer risk
November 2001
FDA cautions about inadequate prostate cancer treatment at Florida facility
After negative prostate biopsy, one more biopsy usually sufficient
GSTP1 methylation level discriminates malignant from benign prostate disease
Routine digital rectal examination uninformative after prostate radiotherapy
Microwave therapy shows promise as treatment for prostate cancer
External radiation for prostate cancer has low impact on near-term quality of life
Whole-pelvic radiation advantageous in prostate cancer with lymph node risk
Most men maintain erectile function after brachytherapy
October 2001
Herbal prostate supplement may cause bleeding
Prostate-specific gene therapy induces apoptosis in prostate cancer cells
High-normal PSA level in middle age indicates elevated risk of prostate cancer
Biennial PSA testing does not increase risk of nonlocalized prostate cancer
September 2001
High calcium intake may boost risk of prostate cancer
Proxima breast cancer brachytherapy device cleared in Canada
Prostate cancers that occur with low PSAs are usually clinically significant
Nomogram helps predict outcome of prostate brachytherapy
Casodex approved in UK for early-stage prostate cancer
Bicalutamide reduces risk of prostate cancer progression
Endocrine-related outcomes similar after surgery or hormone therapy for prostate cancer
August 2001
PSA rise and positive biopsy after brachytherapy may not signal cancer
Prognostic biomarkers identified for prostate cancer
Exisulind improves PSA parameters of men with recurrent prostate cancer
Age-related increases in DNA damage favor development of prostate cancer
Occult spinal cord compression risk can be predicted in prostate cancer patients
Low-fat, flaxseed-supplemented diet may benefit prostate cancer patients
Implant Sciences receives EU approval for prostate cancer brachytherapy seeds
Draxis to market palladium-103 brachytherapy implant in Canada
July 2001
PSA is superior to free-to-total PSA ratio in predicting prostate cancer
Brachytherapy or enucleation for choroidal melanoma yield similar survival rates
Cryoablation reasonably effective and safe for recurrent prostate cancer
Debiopharm wins FDA approval for long-acting prostate cancer therapy
June 2001
Brachytherapy not innocuous for patients with localized prostate cancer
Hormone therapy decreases bone mass in prostate cancer patients
Amgen, Praecis present promising phase III data for prostate cancer treatment
Eating fatty fish may reduce prostate cancer risk
May 2001
Bisphosphonates might reduce bone metastasis in prostate cancer patients
Socioeconomic status linked to prostate cancer incidence in the PSA era
Matritech, Johns Hopkins identify a new prostate cancer marker
April 2001
Prostate cancer nomograms accurate, but effect on decisionmaking unknown
Nerve grafts help maintain erectile function following prostatectomy
Elevated leptin levels associated with increased risk of prostate cancer
Sensitive bone formation marker for prostate cancer metastasis identified
Immediate radiotherapy benefits prostatectomy patients at risk for recurrence
Predictors of biochemical failure after radical prostatectomy identified
Prostate cancer vaccine strategy yields promising results
Use of brachytherapy not supported by published data
Large study of early prostate cancer launched in the UK
Bicalutamide reduces risk of prostate cancer progression by 43%
High dietary boron linked to reduced risk for prostate cancer
Gene identified that may be target for prostate cancer vaccine
March 2001
BRCA2 mutation carriers have an increased risk of prostate cancer
February 2001
FDA clears two immunoassays for prostate cancer
Anti-PSCA antibodies show promise as prostate cancer treatment
Erectile dysfunction risk unrelated to type of prostate cancer treatment
Prostate tumor ablation technique uses implanted magnetic rods
Prostate biopsy affects patient well-being before the procedure
New prostate cancer test promising in early study
January 2001
ProstaScint scans predict prostate cancer recurrence and metastases
FDA grants priority review to Praecis Pharmaceuticals' prostate cancer drug
Prednisone drug of choice for progressive hormone-resistant prostate cancer
November 2000
Adjusted PSA levels useful in detecting prostate cancer
October 2000
Short-course hormone therapy does not benefit low-risk prostate cancer patients
Radiation therapy less costly than surgery for early prostate cancer
Long-term androgen suppression plus radiation increases prostate cancer survival
FDA approves component of Endocare's cell-freezing system for prostate cancer
Lymph node dissection can be omitted in subset of prostatectomy cases
September 2000
Prostate cancer cell growth inhibited in men on diet, exercise program
Elevated p53 levels bring worse prostate cancer prognosis
Percent free PSA increases specificity of prostate cancer detection
Visual examination of prostate tissue predicts recurrence after prostatectomy
Hereditary prostate cancer linked to other malignancies
COX-2 inhibition suppresses prostate cancer in experimental model
Androgen suppression unnecessary for some men with localized prostate cancer
Herbal mixture can reduce PSA levels in men with prostate cancer
Lidocaine safe, effective for topical anesthesia in transrectal prostate biopsy
August 2000
Introduction of p53 suppresses growth, metastasis of prostate cancer in mice
Experimental prostate cancer growth slowed by pHyde gene therapy
FDA clears Nucletron's SPOT imaging software for prostate seed implantation
July 2000
Percent free PSA, not age-specific cutoffs, sensitive in detecting prostate cancer
More extensive biopsy protocol improves prostate cancer detection rate
Androgen receptor gene variation predicts prostate cancer recurrence in low-risk men
Computerized tool detects early prostate cancer
Genentech licenses UroGenesys prostate cancer antigen
AxCell, Institutes for Systems Biology to collaborate on prostate cancer research
Seminal vesicle-sparing radical prostatectomy maintains urinary continence
Stilbestrol effective as salvage therapy for refractory prostate cancer
Immunex licenses UroCor antigens for prostate cancer research
Chromosomal gains correlate with prostate cancer progression after surgery
June 2000
Brachytherapy yields excellent long-term results in prostate carcinoma
Physicians likely to recommend prostate cancer treatments in their specialty
Loss of expression of androgen-receptor isoform detected in colon cancer
Several loci identified as possible hereditary prostate cancer markers
Draxis unit gets brachytherapy patent
Vegan diet may cut risk of prostate cancer
Myriad's prostate cancer finding boosts stocks
Circulating neuroendocrine marker improves prognostic assessment in prostate disease
May 2000
BCG treatment for bladder cancer raises PSA in absence of prostate cancer
Chinese herbal remedy holds promise for prostate cancer
New test predicts later metastasis of initially controlled prostate cancer
Laparoscopy permits more precise dissection during radical prostatectomy
Leuprolide implant provides successful palliative therapy for prostate cancer
Aggressive treatment for early prostate cancer cost -effective
April 2000
Older age is not a reason to delay prostate cancer treatment
Deferred endocrine therapy for prostate cancer yields high rate of morbidity
Doxazosin cytotxic to prostate carcinoma cell lines
Cause of death often misreported for prostate cancer patients
Aggressive prostate cancers form microcirculatory networks
Human glandular kallikrein aids identification of tumor stage in prostate cancer
Prostate-specific antigen bounce common after radioactive seed implantation
March 2000
Carbohydrate-based vaccine benefits prostate cancer patients
Suramin reduces pain, delays progression in hormone-refractory prostate cancer
Prolonged combined androgen blockade may increase survival of prostate cancer patients
Free PSA percentage effective for prostate cancer detection in black men
Decline in prostate cancer mortality supports benefit of early PSA screening
OCs may protect against ovarian cancer in part via direct antiandrogen effects
February 2000
FDA approves Syncor's palladium "seeds" for prostate cancer treatment
January 2000
Erectile dysfunction likely after radical prostatectomy for prostate cancer
Prostatectomy, radiation equally effective in treatment of low-risk prostate cancer
No link found between vasectomy and prostate cancer
PSA nadir of 0.2 ng/mL or less after irradiation represents cure of prostate cancer
Vegetables lower prostate cancer risk
December 1999
PSA level predicts prostate growth in patients with benign prostatic hyperplasia
Cryosurgery and video MRI eradicates renal cancer
FISH analysis predicts prostate cancer progression
Immediate hormonal therapy superior to observation after surgery for node-positive prostate cancer
November 1999
Biochemical failure does not predict survival after radical prostatectomy
Higher surgical volumes bring better prostatectomy outcomes
Equal outcomes seen with radiation or surgical therapy for prostate cancer
Smoking history adversely affects potency after prostate cancer treatment
Beta-carotene supplements may decrease prostate cancer risk in men with low levels
October 1999
Genetically engineered prostate cancer vaccine activates entire immune system
Consistently normal PSA levels suggest cure after radiation for prostate cancer
Endorectal MRI may aid in identifying high-risk men with prostate cancer
Digital exam, imaging unnecessary if PSA undetectable after prostatectomy
Preoperative percent free PSA a predictor of pathologic outcome after radical prostatectomy
September 1999
Chromosome 8 alterations linked to prostate cancer progression
Prostate cancer risk affected little by fat intake
Anti-bcl-2 ribozyme effective against hormone sensitive, resistant prostate cancer in culture
August 1999
Percentage of free PSA identifies prostate cancer risk in subset of men
July 1999
Antioxidant vitamins inhibit role of androgens in prostate cancer development
Outcome better with adjuvant rather than salvage radiation after prostatectomy
Bicalutamide as effective as maximum androgen blockade in treating advanced prostate cancer
June 1999
Mitoxantrone, prednisone combination effective for end-stage prostate cancer
Apoptosis markers help predict response to radiotherapy in patients with localized prostate cancer
NCI issues 5-year plan for prostate cancer research
High-flux dialysis decreases levels of prostate cancer marker
May 1999
Incidence of aggressive prostate tumors increasing in the Netherlands
Bone loss seen with androgen suppression therapy for prostate cancer
Overall mortality rate in US for prostate cancer reported
April 1999
Massachusetts hospital acknowledges 20 prostate biopsies misread between 1995 and 1997
Combination of total PSA, percent free PSA indicates risk of prostate cancer
Soy components reduce growth, metastasis of human prostate cancer cells in murine studies
E-cadherin expression appears to indicate progression of prostate cancer
Growth hormone implicated in increased prostate cancer risk among African Americans
Endothelin-receptor antagonist reduces pain of advanced prostate cancer
ASTRO issues guidelines on radiation therapy for prostate cancer
Neoadjuvant androgen ablation seems to add little to prostatectomy outcome
Androgen receptor expression of predictive value in patients with advanced prostate cancer
March 1999
Suramin may be useful in a subset of patients with refractory prostate cancer
Radical prostatectomy in node-positive prostate cancer appears beneficial
Race not an independent risk factor for positive prostate biopsy
Scotia to evaluate Foscan for lung, prostate cancers
Energy restriction reduces prostate tumor growth in rats
Amgen licenses rights to phase III prostate cancer drug
Tumor grade best predictor of outcome following radiotherapy for prostate cancer
Molecular mechanisms involved in prostate cancer development identified
February 1999
Survival advantage seen with initial radiotherapy for localized prostate cancer
January 1999
Prostate cancer progresses earlier, more likely to recur in African Americans
Conformal radiation of prostate reduces risk of bowel side effects
Digital exam and biopsy do not accurately gauge extent of prostate cancer
Age a stronger predictor of curable prostate cancer than PSA
Sildenafil ineffective in patients following non-nerve-sparing radical prostatectomy